Lycera Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lycera Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10854
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lycera Corp (Lycera) is a biopharmaceutical company that focuses on the development of oral immune modulators for the treatment of patients with autoimmune diseases and cancer. The company’s pipeline products include LYC-55716, an oral retinoic acid-related orphan receptor gamma (RORgamma) agonist which is in Phase 1/2a ARGON trial that modulates gene expression to reprogram immune cells for improved function and decrease immunosuppressive mechanisms. It also develops novel ATPase modulators for the treatment of autoimmune diseases; and immuno-oncology targets. Lycera is headquartered in Ann Arbor, Michigan, the US.

Lycera Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lycera Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lycera Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lycera Corp, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Lycera Raises US$4 Million In Venture Financing 10
Lycera Raises Additional US$21 Million In Venture Financing 11
Partnerships 12
Lycera Enters into Co-Development Agreement with Celgene 12
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 13
Licensing Agreements 14
Celgene Exercises Option for Licensing Agreement with Lycera 14
Lycera Corp – Key Competitors 15
Lycera Corp – Key Employees 16
Lycera Corp – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
Mar 13, 2017: Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors 18
Product News 19
May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Lycera Corp, Pharmaceuticals & Healthcare, Key Facts 2
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lycera Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lycera Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Lycera Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lycera Raises US$4 Million In Venture Financing 10
Lycera Raises Additional US$21 Million In Venture Financing 11
Lycera Enters into Co-Development Agreement with Celgene 12
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 13
Celgene Exercises Option for Licensing Agreement with Lycera 14
Lycera Corp, Key Competitors 15
Lycera Corp, Key Employees 16
Lycera Corp, Other Locations 17

List of Figures
Lycera Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lycera Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lycera Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lycera Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genesis Energy Ltd:発電所・企業SWOT分析
    Genesis Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Kkr Financial Holdings Llc:企業の戦略・SWOT・財務分析
    Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report Summary Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tom N Toms Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Laboratorios Liomont SA de CV:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios Liomont SA de CV (Liomont) is a pharmaceutical company that develops medication products. The company offers prescription medication products, biotech products and over the counter products. It provides drugs in various therapeutic areas including analgesics, antiparasitic, anti …
  • Kohler Co.:企業の戦略・SWOT・財務分析
    Kohler Co. - Strategy, SWOT and Corporate Finance Report Summary Kohler Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • PT Jasa Marga (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Jasa Marga (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Jasa Marga (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • JALUX Inc:企業の戦略・SWOT・財務情報
    JALUX Inc - Strategy, SWOT and Corporate Finance Report Summary JALUX Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Pets at Home Limited (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Limited (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • International AIDS Vaccine Initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary International AIDS Vaccine Initiative (IAVI) is a not-for-profit organization that develops preventive HIV vaccine candidates. The organization offers vaccine development through basic research, discovery, preclinical evaluation and manufacturing, and regulatory review, among others. Its pro …
  • Seattle Genetics Inc (SGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The company's lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate indicated for the treatment of relapsed …
  • BioDiem Ltd:企業の戦略的SWOT分析
    BioDiem Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Vanderbilt University Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Vanderbilt University Medical Center (VUMC), a subsidiary of Vanderbilt University is a healthcare service provider that offers patient care, research and bio-medical education. The center’s services include adult emergency services, case management, corporate health services, adult psychiat …
  • DSK Bank EAD :企業の戦略・SWOT・財務情報
    DSK Bank EAD - Strategy, SWOT and Corporate Finance Report Summary DSK Bank EAD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • ARCA biopharma Inc (ABIO):医療機器:M&Aディール及び事業提携情報
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Campbell Soup Company:企業の戦略・SWOT・財務情報
    Campbell Soup Company - Strategy, SWOT and Corporate Finance Report Summary Campbell Soup Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bullfrog Power Inc.-エネルギー分野:企業M&A・提携分析
    Summary Bullfrog Power Inc. (Bullfrog Power) is a provider of green energy. The company offers renewable energy solutions that help businesses and houses in reducing their environmental impact. Bullfrog's product portfolio includes green electricity, green fuel and green natural gas. The company, th …
  • The Brink’s Company:企業の戦略・SWOT・財務情報
    The Brink's Company - Strategy, SWOT and Corporate Finance Report Summary The Brink's Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Gamida Cell Ltd:企業のM&A・事業提携・投資動向
    Gamida Cell Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gamida Cell Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Parker Hannifin Corporation (PH)-医療機器分野:企業M&A・提携分析
    Summary Parker Hannifin Corporation (Parker) is a manufacturer of motion and control technologies and systems. The company offers critical motion and control solutions including fluid power systems, electromechanical controls and related components. Its products find use in various industries and ap …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆